Loading…
← CockpitCompetitor Analysis › TATVA.NS Tatva Chintan Pharma Chem LimitedOpen in the cockpit ↗

Tatva Chintan Pharma Chem LimitedTATVA.NSCompetitor analysis, valuation and peers

India · INR·Chemicals›Chemicals: Specialty
Momentum strong 65
Mkt cap
$412M
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$1.41M
20-day average traded
Fwd P/E
49.8×
forward earnings
ROIC−WACC
-9.0 pp
WACC 15.7%
Hurdle
n/a
no reverse DCF
Next earnings
64 days
21 Jan 2027
Close · INR₹1,649
1D-0.7%
1W-0.4%
1M-13.4%
3M-1.2%
6M+28.6%
YTD+23.6%
1Y+9.4%
ATR %4.8%
Beta1.07
52w lowhigh22.0% off high

What Tatva Chintan Pharma Chem does

Employees: 1,097

Tatva Chintan Pharma Chem at a glance

Size Tatva Chintan Pharma Chem (TATVA.NS) is an India Materials company (Chemicals: Specialty) with a market value of $412M, the 941st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,649 on 18 Nov 2026.

Performance Over six months the shares gained 28.6%, against -18.0% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 49.7% over the last twelve months (peer median +5.8%); the operating margin is 13.3% (peer median 5.3%).

Valuation It trades at 49.8× forward earnings against a peer median of 16.5× (most expensive of 8).

Capital Return on invested capital runs 9.0 points below its cost of capital (15.7% WACC).

Next results Next results expected around 21 Jan 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026TATVA.NS 133Peer median 83
Six months, rebased to 100: Tatva Chintan Pharma Chem against the median of its 20 peers (local-currency closes).

Tatva Chintan Pharma Chem financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹6.50B₹5.03B₹3.82B₹3.93B₹4.23B
Revenue growth—+32%-3%-7%—
Gross profit₹2.48B₹1.07B₹464M₹725M₹928M
EBITDA₹1.27B₹1.00B₹374M₹678M₹675M
Net income₹629M₹421M₹57.1M₹304M₹455M
Free cash flown/a-₹841M-₹524M-₹337M-₹1.78B
Capital expendituren/a₹1.14B₹763M₹1.29B₹2.03B
Total debt₹1.70B₹1.20B₹364M₹143M₹1.70B

Quarterly statements and history in the cockpit →

Tatva Chintan Pharma Chem competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%0026661710300239006650ELLENGEVO001367BAK3001324097603798300927603725603192000707VISHNU13130013351714TATVA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Tatva Chintan Pharma Chem is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×20×40×1710006650ELLENGEVOBAK300132VISHNUTATVA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tatva Chintan Pharma Chem is the large dot.

Tatva Chintan Pharma Chem competitors and peer comparison

How Tatva Chintan Pharma Chem compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tatva Chintan Pharma Chem against its 20 peers (data as of 18 Nov 2026)
MeasureTATVA.NSPeer medianRank in peer set
1-month return-13.4%-10.3%7th lowest of 21
6-month return+28.6%-18.0%3rd highest of 21
Distance from 52-week high-22.0%-41.5%3rd highest of 21
Revenue growth (TTM)+49.7%+5.8%4th highest of 21
Operating margin13.3%5.3%3rd highest of 21
Forward P/E49.8×16.5×most expensive of 8
ROIC minus cost of capital-9.0 pp-2.2 pp2nd lowest of 21
EV / EBITDA31.7×8.7×most expensive of 7
Net debt / EBITDA1.2×2.4×5th least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tatva Chintan Pharma Chem TATVA.NSIndia$412M+29%+50%13%49.8×n/an/a
Guangdong Delian 002666.SZChina$410M-30%+3%0%n/an/an/a
Oriental Union Chemical 1710.TWTaiwan$409M+41%+1%0%16.1×n/an/a
Baotou Dongbao Bio-Tech 300239.SZChina$408M-14%+7%7%n/an/an/a
KPIC 006650.KSSouth Korea$405M-40%+11%4%8.9×n/an/a
Ellenbarrie Industrial Gases ELLEN.NSIndia$420M0%+289%28%24.6×42.8%+14.3%
Gevo GEVOUnited States$421M+4%+80%-11%24.8×n/an/a
Zhejiang Haisen Pharmaceutical 001367.SZChina$404M-24%+9%29%n/a-3.9%+13.4%
Braskem S.A. Sponsored ADR Pfd BAKUnited States$421M-82%-1%1%1.6×n/an/a
FuJian Nox Bellcow 300132.SZChina$422M-32%+18%7%16.5×-4.3%-10.5%
Koatsu Gas Kogyo 4097.TJapan$423M+10%+4%7%n/a-9.6%+5.1%
Qingdao Copton Technology 603798.SSChina$401M-43%-7%5%n/a19.9%+0.9%
Nantong Jiangtian Chemical 300927.SZChina$425M-32%+51%5%n/a16.3%+29.0%
Guangdong Tianan New Material 603725.SSChina$425M-10%-12%2%n/a19.4%+29.0%
Shanghai Huide Science & Technology 603192.SSChina$426M-22%+10%3%n/a9.0%+10.5%
Hubei Shuanghuan Science and Technology 000707.SZChina$399M-11%-10%-10%n/a56.5%+3.1%
Vishnu Chemicals VISHNU.NSIndia$398M-8%+14%13%20.1×n/an/a
UPC Technology 1313.TWTaiwan$435M+9%-1%0%n/a38.2%+2.5%
Zhejiang Jianye Chemical 603948.SSChina$438M-36%-5%12%n/a-4.3%+3.5%
Trust Chem 001335.SZChina$388M-40%+5%7%n/a24.6%+5.6%
Ho Tung Chemical 1714.TWTaiwan$388M+40%+48%10%n/a-20.6%-1.5%

Questions

Which companies are Tatva Chintan Pharma Chem's closest peers?
The cockpit's peer set: Guangdong Delian (002666.SZ), Oriental Union Chemical (1710.TW), Baotou Dongbao Bio-Tech (300239.SZ), KPIC (006650.KS), Ellenbarrie Industrial Gases (ELLEN.NS), Gevo (GEVO), Zhejiang Haisen Pharmaceutical (001367.SZ), Braskem S.A. Sponsored ADR Pfd (BAK).
Is Tatva Chintan Pharma Chem expensive compared with its peers?
On forward p/e it trades at 49.8× against a peer median of 16.5×, most expensive of 8 in its peer set.
How has Tatva Chintan Pharma Chem stock performed?
Over six months to 18 Nov 2026 the shares returned +28.6% against -18.0% for the median peer; over one year +9.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.